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Abstract
Background: Evidence-based practice in eating disorders incorporates three essential components: research
evidence, clinical expertise, and patient values, preferences, and characteristics. Conceptualized as a ‘three-legged
stool’ by Sackett et al. in 1996 (BMJ), all of these components of evidence-based practice are considered essential
for providing optimal care in the treatment of eating disorders. However, the extent to which these individual
aspects of evidence-based practice are valued among clinicians and researchers is variable, with each of these
stool ‘legs’ being neglected at times. As a result, empirical support and patient preferences for treatment are not
consistently considered in the selection and implementation of eating disorder treatment. In addition, clinicians
may not have access to training to provide treatments supported by research and preferred by patients. Despite
these challenges, integrating these three components of evidence-based practice is critical for the effective
treatment of eating disorders.
Discussion: Current research supports the use of several types of psychotherapies, including cognitive-behavioral,
interpersonal, and family-based therapies, as well as certain types of medications for the treatment of eating disorders.
However, limitations in current research, including sample heterogeneity, inconsistent efficacy, a paucity of data, the
need for tailored approaches, and the use of staging models highlight the need for clinical expertise. Although
preliminary data also support the importance of patient preferences, values, and perspectives for optimizing
treatment, enhancing treatment outcome, and minimizing attrition among patients with eating disorders, the
extent to which patient preference is consistently predictive of outcome is less clear and requires further
investigation.
Summary: All three components of evidence-based practice are integral for the optimal treatment of eating
disorders. Integrating clinical expertise and patient perspective may also facilitate the dissemination of
empirically-supported and emerging treatments as well as prevention programs. Further research is imperative
to identify ways in which this three-legged approach to eating disorder treatment could be most effectively
implemented.
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Background
Increasingly, clinicians in all areas of health services are
being encouraged to engage in evidence-based practice.
Evidence-based practice encourages clinicians to (1)
use the best available research evidence in conjunction
with (2) clinical expertise, whilst (3) considering patients’
characteristics, values, and circumstances to inform care
[1]. These three aspects have been referred to as the
‘three-legged stool’ of evidence-based practice [1, 2].
Many clinicians and researchers, however, appear to
consider the construct ‘evidence-based practice’ as syn-
onymous with ‘evidence-based treatments’ or ‘empiric-
ally-supported therapies’. These latter constructs are
solely concerned with research evidence supporting par-
ticular interventions, whereas evidence-based practice has
the additional strands of clinical expertise and patient char-
acteristics. Nevertheless, clinicians often appear to discount
research evidence – the first leg of the stool—for a variety
of reasons, including perceived differences between samples
in clinical trials and those in routine clinical settings [3].
Within the area of eating disorders in particular, this
disregard has led to the majority of patients not receiving
treatment demonstrated to be efficacious in randomized
controlled trials [4]. Indeed, figures from the UK suggest
that only 4 % of family physicians used published clinical
guidelines in the treatment of eating disorders [5].
The significant reservations about data from clinical
research studies, coupled with concern about specific
techniques such as those used in cognitive-behavioral
therapy (CBT) [6], suggest that decision-making regarding
treatment selection is often guided by the remaining ‘legs’
of the three-legged stool. For example, surveys indicate that
some therapists tend to rely on their clinical experience or
that of their peers in their clinical decision-making rather
than on research [7]. However, clinical experience has been
shown to be subject to a number of significant biases [8]
and basing decision-making purely on clinical experience is
likely to contribute to ‘therapist drift’ from protocols that
may negatively impact therapy and make it difficult to
maintain treatment integrity [9]. On the other hand,
limitations in research, including the lack of data on
clinical interventions for some conditions, can complicate
the extent to which empirical findings can inform treat-
ment. With regards to the final leg of the stool, namely the
consideration of patient characteristics, values, and circum-
stances to inform care, relatively little research has been
conducted on the role of patient preferences in clinical
decision-making in the treatment of eating disorders, but
the emphasis on patient choice indicates that clinicians are
increasingly aware of the importance of patient preferences
and values in determining treatment strategies.
The issues arising from using only one of the ‘legs’—i.e.
research evidence or clinical judgement or patient
values—to guide clinical decision-making are multiple
and profound. Further, understanding that the foundations
of evidence-based practice are grounded in the combin-
ation of each of these three elements is the necessary first
step for the improvement of patient treatment as well as
towards the integration of all three ‘legs’ of the stool in
evidence-based practice. Regular progress monitoring and
feedback using tools developed from, and used by, re-
search can help guide clinical decision-making and may
also influence patient values [10, 11]. The implementation
of flexible treatment manuals to facilitate fidelity to the
protocol allows clinicians to be fully creative and to
personalize treatment to clients, thus harnessing clinical
judgement and skills [12]. In order to achieve this,
changing the methods by which research findings are
communicated to increase their relevance to clinicians
is fundamental. In addition, ensuring that participants
studied in research are representative of clinical samples
in terms of comorbidities, ethnicity, socioeconomic status,
and other variables, as well as the publishing of negative
results, would help bridge the gap between science and
practice.
The inherent problems in the use of evidence-based
practice are not specific to eating disorders or mental
health; rather, they impact across multiple spheres, in-
cluding medicine and public health [13]. Nevertheless, in
eating disorders in particular, there is increasing interest
in attempting to understand and resolve some of the dif-
ficulties with a view to improving clinical outcomes.
Such growing interest led to a symposium being con-
vened at the London 2015 Eating Disorders Conference
in March 2015, entitled The Three-Legged Stool of
Evidence-Based Practice: Research, Clinical, and Patient
Perspectives, with the aim to implement each of the
‘legs’ of the stool in evidence-based practice. The three
‘legs’ are summarized below.
Discussion
Research evidence
As specified by Sackett et al. [1], the research ‘leg’ of the
evidence-based stool relies on the most current empir-
ical evidence of treatment efficacy and effectiveness
based on randomized controlled trials (ideally, double-
blinded), meta-analyses, systematic reviews, case series,
and other types of research designs. Determining treat-
ment based on findings from research investigations,
particularly using well-designed studies, minimizes the
occurrence of clinical biases in treatment selection [3, 8]
and helps ensure that patients receive the optimal treat-
ment based on current findings.
Current research data suggest that cognitive behavioral
approaches, including enhanced CBT (CBT-E) [14] as
well as CBT-guided self-help, have been most efficacious
among adults with bulimia nervosa and binge eating dis-
order; data supporting the use of CBT for adults with
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anorexia nervosa and adolescents with eating disorders
are more inconsistent [15–22]. Similarly, the use interper-
sonal therapy (IPT) to treat eating disorder symptoms is
primarily supported in adults with bulimia nervosa and
binge eating disorder, with preliminary treatment outcome
data suggesting that dialectical behavior therapy (DBT)
may also be promising in these populations [15–18]. For
adolescents with anorexia nervosa or bulimia nervosa,
family-based treatments (FBT) have been found to be
associated with significant improvements, although com-
parable adolescent-focused treatments (AFT) have also
shown promise [15, 16, 20, 21, 23]. Finally, selective sero-
tonin reuptake inhibitors and tricyclic antidepressants
have been associated with reductions in eating disorder
symptoms in bulimia nervosa and binge eating disorder
with more modest support for the use of topiramate; in
contrast, minimal empirical evidence has been found for
the use of medications in the treatment of anorexia ner-
vosa [16, 20]. In randomized trials, the added benefit of
pharmacotherapy when combined with psychotherapy has
received inconsistent support for the treatment of eating
disorders, with a few studies finding a significant effect for
combined treatment [24] and others finding minimal addi-
tive effects [25, 26].
Although potentially useful in guiding treatment selec-
tion, consistent predictors of treatment outcome have not
been identified in eating disorders. One notable exception
is rapid response in CBT: among individuals with bulimia
nervosa and binge eating disorder, significant symptomatic
reduction in the first month has been associated with better
outcome at end of treatment [27, 28]. This robust finding
has important clinical implications, especially in the context
of stepped care models. More recently, increasing attention
has been focused on identifying treatment-specific modera-
tors and mediators that can be used to optimize treatment
selection [29]. Preliminary support for several treatment-
specific moderators has been found in randomized con-
trolled eating disorder treatment studies. More specifically,
adults with severe and enduring anorexia nervosa who were
older, classified as binge eating and purging subtype, and
with higher levels of depression and global eating disorder
psychopathology showed greater improvement in CBT than
in specialist supportive clinical management [30]. For
adolescents with anorexia nervosa who received FBT or
AFT, those with higher baseline levels of eating-related
psychopathology and obsessionality benefited more from
FBT than AFT at end of treatment [31]. Adolescents with
bulimia nervosa who reported higher levels of purging at
baseline, as well as those who were younger, showed
greater improvement in FBT than in supportive psycho-
therapy [32]; a previous study also observed that FBT was
associated with better outcomes for participants who
reported lower scores on global eating disorder psycho-
pathology (e.g. eating, weight, and shape concerns) [33].
Additionally, a recent study found that participants with
symptoms of bulimia nervosa who reported higher levels
of stimulus seeking and affective instability showed more
improvement in integrative cognitive-affective therapy
than in CBT; individuals lower in stimulus seeking had
better treatment outcome in CBT than in integrative
cognitive-affective therapy [34]. Another recent study ob-
served that, for participants with both bulimia nervosa
and borderline personality disorder, the broad version of
CBT-E was associated with better outcome compared to
the focused version for those who reported high levels of
baseline emotional and interpersonal distress; participants
with lower levels of emotional and interpersonal distress
reported more improvement with the focused version of
CBT [35]. For binge eating disorder, a randomized trial
found that those with avoidant personality disorder and
early onset overweight and dieting had poorer outcome in
an active control condition than in DBT [36]. Overvalu-
ation of shape and weight has also been identified as a
treatment moderator in binge eating disorder as it was as-
sociated with better outcome in CBTcompared to psycho-
pharmacological treatment, even when controlling for
negative affect [37]. In the same study, younger patients
had better outcome with fluoxetine, whereas higher levels
of baseline negative affect and binge eating frequency and
lower levels of self-esteem were associated with better
outcome in CBT; in addition, older age of onset of binge
eating disorder was associated with more rapid improve-
ments in CBT [37]. Another randomized trial for the
treatment of binge eating disorder found that higher levels
of eating disorder psychopathology and lower self-esteem
were associated with better outcome in CBT and IPT
compared to CBT-guided self-help [38]. Finally, in a
heterogeneous eating disorder sample, participants with
lower self-esteem and higher levels of mood intolerance,
interpersonal difficulties, and clinical perfectionism showed
improved response to the broad version of CBT-E com-
pared to the focused version [39].
In contrast to the growing list of potential moderators
of treatment, identification of mediators remains more
elusive. Although potential treatment mediators, includ-
ing motivation [40] and obsessive compulsive symptoms
[41], have been observed in naturalistic studies, signifi-
cant mediators have not been identified in randomized
treatment trials [e.g. 31]. In summary, rapid response in
CBT appears to be a robust predictor of outcome; alter-
native or adjunctive treatments should be considered
for patients with eating disorders who do not show ini-
tial improvement with CBT. Although preliminary data
support several treatment-specific moderators, replica-
tion and robust data are needed to implement these
empirical findings in clinical settings for treatment se-
lection. Further research is needed to identify treatment
mediators.
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Empirical examinations of emerging treatments for eat-
ing disorders are underway, including couples and family
treatment for adult patients, carer interventions, cognitive
remediation, mindfulness approaches, emotion-focused
therapies, acceptance and commitment therapy, and add-
itional pharmacological agents. In addition, innovative
treatment delivery is being investigated using the internet
and mobile phones. Empirically-informed stepped-care
and staging models may also improve treatment outcome.
An increasing focus on identifying causal and mainten-
ance mechanisms and an understanding of their psycho-
logical and neurobiological manifestations will ideally
facilitate treatment targets among emerging treatments as
well as strengthen the likelihood of identifying moderators
that can be used to determine which treatments work
optimally for which patients [29, 42]. Another critical
consideration is the dissemination and implementation
of evidence-based treatments given that clinicians often
site the lack of training and expertise for their decreased
likelihood to use these interventions [43]. Thus, scalability
is an important feature of evidence-based treatments.
Although the importance of using research to guide
treatment cannot be overemphasized, limitations in
treatment research highlight the value of considering
empirical findings in the context of both clinical ex-
pertise and patient preferences and values. First, despite
impressive effect sizes in many trials, eating disorder
treatment outcome studies are generally characterized
by significant rates of attrition, relapse, and non-remission
[16, 18, 19]. In addition, with the exception of CBT-E [14],
most eating disorder treatments have been developed for
one type of eating disorder (e.g. bulimia nervosa, anorexia
nervosa, or binge eating disorder) and have not been
tested in samples that include subthreshold or mixed diag-
nostic symptoms despite the high prevalence of these
cases in clinical settings [44, 45]. Many trials have not in-
cluded males, youth, or individuals with certain types of
comorbid psychopathology (e.g. substance use disorder),
or ethnically diverse samples. Notably, although best prac-
tices often utilize inpatient, residential, partial, day treat-
ment, and intensive settings, minimal data are available
for treatment delivered in settings other than outpatient
settings. Additionally, the rigors of the scientific process
make the incorporation of novel and experimental treat-
ments into the evidence base slow. Therefore, the use of
clinical expertise and patient values and preferences along
with empirical support in determining eating disorder
treatment has a number of advantages. First, the com-
bined perspective will potentially increase ecological valid-
ity and identify treatments that may not be acceptable to
patients, regardless of empirical support. Further, the add-
itional legs will contribute to the development of novel
treatments that can eventually be tested and added to the
body of evidence-based treatments. Finally, the use of
clinical expertise along with patient preferences and values
can potentially help guide treatment dissemination and
prevention strategies.
Clinical expertise
Clinical expertise remains a critical component of eating
disorder treatment given that several questions and
concerns remain inadequately addressed by the existing
research literature. For instance, even the diagnosis or
the ‘what’ of an eating disorder is of limited utility for
guiding management as additional aspects such as how
much, why, and with what also play crucial roles. In
this context, clinical expertise and assessment skills are
essential. Diverse psychological comorbidities are also
embedded within the eating disorder spectrum, and
physical state ranges from severe undernutrition to
hyperalimentation. Moreover, the case formulation needs
to include age, stage, and the psychosocial context [46].
Thus, matching diagnosis to evidence-based treatment
while considering patient characteristics and preferences
is a complex art.
This complexity is recognized, in part, within the
DSM-5 [47] description of anorexia nervosa, which
now uses a body mass index scale to provide a range
of severity. However, although body mass index is a proxy
measure of risk, other factors should also be considered,
such as the rate of weight loss, fluid and electrolyte dis-
turbance, markers of metabolic and cardiovascular risk,
and pubertal stage, sex, ethnic group, duration of illness,
and comorbidity. There are wide cultural variations in
how cases with high risk are matched to service/treatment
as well as the form and content of such treatment. For ex-
ample, cultural factors may impact the extent to which
treatment is legally mandated as well as whether patients
are able to refuse treatment and the selection of treatment
settings (e.g. outpatient versus hospital based). The field
has moved from the position advocated by Gull 150 years
ago, where everyone was admitted to hospital because
“family and friends are the worst attendants” [48], to in-
volving the family and limiting inpatient care to those at
extreme risk. In addition, the goal of admission for adoles-
cent cases is to ameliorate risk rather than attain full
weight restoration.
Time is of the essence. Prepubertal cases of anorexia
nervosa have more acute and complex longer term risks.
In addition, the duration of untreated illness (either the
result of delay in presentation or because of a failure to
respond to treatment) is a key prognostic indicator [49].
One hypothesis is that neuroadaptive changes to persist-
ent starvation and abnormal eating behaviors result in
treatment resistance [46, 50]. This conceptualization has
fostered the development of brain-directed treatments
that use learning to remediate inflexibility and detailed
thinking or train attention away from specific eating
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disorder salient or more general threat cues as well as
neuromodulation to modify mood or habitual behaviors.
The diversity in causal and maintaining factors is now
accepted, although how this complexity of factors should
be assessed and addressed is still in the early stages.
Many evidence-based treatments are modularizing treat-
ment so that specific targets can be addressed. For ex-
ample, CBT-E has three optional treatment modules that
address interpersonal difficulties, core low self-esteem, and
clinical perfectionism [14]. The Maudsley Model of
Anorexia Nervosa Treatment for Adults (MANTRA)
also includes a case formulation and nine treatment
modules, including interpersonal relationships, emotional
regulation, and cognitive remediation [51]. Despite these
clinical and scientific advances in modular treatments,
however, dissemination and implementation of evidence-
based treatments are essential to enable clinicians to
utilize these state-of-the-art interventions in selecting and
personalizing clinical interventions. In addition, the extent
to which clinicians are trained to provide treatments that
are selected and preferred by patients is a critical consider-
ation in the context of implementing evidence-based
practice.
In conclusion, we are still at the early stages of person-
alized care in eating disorders; however, with advances
in defining brain-specific pathways from genetics and
neuroscience, clinical expertise is essential in terms of
tailoring treatment.
Patient values and preferences
The third leg of the evidence-based stool consists of patient
values and perspectives [1]. With regards to mental health,
researchers typically study patient values and perspectives
under the headings of patient preferences and expectancies;
this section explores three questions with respect to these
factors. First, do patient preferences and expectations
actually matter in eating disorder treatment? Second,
can providers improve outcome expectancies (and, likely,
preferences)? Third, what aspects of eating disorder psy-
chopathology complicate the reliance on patient prefer-
ences (e.g. desire to remain underweight)?
Patient preferences are best understood as something
desired by patients [52]. For instance, patients might
prefer psychotherapy over medication, a particular type
of psychotherapy (e.g. behavioral), or a particular type of
therapist (e.g. based on sex, age, or ethnicity). Patient ex-
pectancies involve predictions. Role expectancies consist
of what patients anticipate will happen in treatment (e.g.
the process); outcome expectancies include predictions
about the effectiveness of treatment and the probability
of improvement [53, 54]. Outcome expectancies are a
form of response expectancies, which underpin both the
placebo and nocebo responses, and play a key role in the
efficacy of many treatments [55].
With regards to the first question about the importance
of patient preference, we contend that patient preferences
and expectations likely influence eating disorder treatment
for two reasons. First, eating disorders are associated with
high rates of attrition [56, 57], and research suggests that
failure to attend to patient preferences in psychotherapy
increases dropout [57, 58]. Using non-eating disorder
psychiatric samples, several studies have observed that
matching treatment with patient preferences reduced
attrition for a range of disorders (e.g. anxiety, depression,
substance abuse) and may be associated with improved
outcomes [59–61]. Further, some evidence suggests that
lower outcome expectancies also increase attrition [62].
However, other randomized controlled trials of psychiatric
samples have found no significant effect for treatment
preferences on attrition or outcome [63], with others
suggesting that the impact may depend on the strength
of the preference [64]. The extent to which findings
from other types of psychiatric disorders can be gener-
alized to eating disorders is unclear, particularly given
that eating disorders are often associated with high
rates of treatment refusal [65].
Despite the lack of clarity regarding the consistent
impact of patient preferences on treatment outcome in
psychiatry research, an additional consideration is the
extent to which data support an association between
outcome expectancies and treatment outcome [54]. In
other words, patients who expect to do well with a given
treatment are more likely to benefit than those who hold
lower expectations. Importantly, outcome expectancies
have long been viewed as a key common factor for good
psychotherapy outcome [62, 66]. Constantino et al. [67]
found that outcome expectancies significantly predicted
treatment alliance in eating disorders, which is important
as therapeutic alliance itself has been consistently found
to predict treatment outcome [68–70]. Although the
relationships between expectancies, patient preferences,
and treatment outcomes are unclear, some evidence
suggests that preferences for CBT versus pharmacotherapy
moderate response to both interventions [61, 71]. How-
ever, further research is needed. To summarize, patient
preferences and expectancies are likely to have an impact
in eating disorder treatment since both appear to influence
attrition; outcome expectancies also consistently appear to
influence treatment outcome and some preferences appear
to moderate outcome. Nonetheless, research addressing
these topics in eating disorder samples is needed.
With regards to the second question about the extent
to which clinicians can influence outcome expectancies,
minimal research has been conducted with eating disorder
patients. Yet, as noted above, outcome expectancies have
been discussed as a key component to psychotherapy; in-
deed, some writers view psychotherapy as “inextricably
linked with the manipulation and revision of patients’
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expectations” ([72], p. 671). For instance, CBT provides a
rationale for treatment, which theoretically improves cred-
ibility and provides a reason to believe that treatment can
work. CBT therapists also typically provide patients with
an overview of research support for CBT, which leads to
further evidence of treatment effectiveness. Similarly,
research clearly shows that outcome expectancies influ-
ence the efficacy of pharmacotherapy and such studies
require manipulation of expectancies [73]. Thus, we
contend that there appears to be evidence in both the
psychotherapy and pharmacotherapy fields that sug-
gests outcome expectancies for treatment can be im-
proved; further, improved outcome expectancies may
drive some shift in preferences. Kirsch [74] suggests the
following strategies for enhancing outcome expectan-
cies: (1) create a strong therapeutic relationship, which
improves confidence in the provider and what they say,
(2) foster confidence in treatment effectiveness, anticipa-
tion of substantial change, and expectation that change
will occur slowly so that faster than expected change can
positively snowball expectancies, along with an attitude
that one must work to achieve change.
A third consideration is the complexity of relying on
patient preference given the nature of eating disorder
psychopathology and the frequency of treatment refusal
and ambivalence among individuals with eating disor-
ders, particularly anorexia nervosa [65]. Indeed, the fear
of weight gain and overvaluation of shape and weight
that characterize eating disorders [47] may result in
the rejection of interventions that serve as the basis of
evidence-based treatment (e.g. self-monitoring, meal
planning, behavioral exposure, consumption of feared
foods, weight restoration to improve medical and cogni-
tive status, involvement of family members). Alternatively,
eating disorder psychopathology may influence the
preference of treatments that potentially lead to weight
loss (e.g. topiramate as a medication for binge eating).
Given that these clinical features may, in fact, contribute
to the maintenance of eating disorders, incorporating pa-
tient preference into treatment selection among individ-
uals with eating disorders may be especially problematic
and complicate treatment outcome. An additional consid-
eration is that patients may express preferences for treat-
ments that have been found to be ineffective in research
trials. This scenario is especially problematic because it
enables the patient to believe that they are engaged in
treatment and yet they are not actually receiving an effect-
ive intervention. In evidence-based practice, clinicians
must navigate the complexity of respecting patient desires
while also relying on data and expertise to collaboratively
identify more potentially efficacious treatment options.
Finally, recognizing the potential influence of therapist
factors on treatment selection, including anxiety [75], and
which may interact with expressed patient preference, can
help guide the clinician in treatment selection by recogniz-
ing potential vulnerabilities and biases.
In summary, minimal research has been conducted on
the effects of treatment preference on outcome and attri-
tion among patients with eating disorders; nevertheless,
data from non-eating disorder psychiatric samples provide
some support for the potential positive impact of patient
preference on treatment outcome. The frequent occur-
rence of treatment refusal and ambivalence among indi-
viduals with eating disorders makes future investigations
to determine the impact of treatment preference in eating
disorders especially important.
Summary
In summary, each ‘leg’ of evidence-based practice provides
an integral component of eating disorder treatment. The
three-legged stool nonetheless requires extensive data, ex-
pertise, and knowledge to ensure that each leg is equally
sturdy. Research indicates that, for the treatment of bulimia
nervosa and binge eating disorder, CBT and IPT have
strong empirical support whereas DBT and certain types of
medications have modest support. FBT has been found to
be efficacious in children and adolescents with anorexia
nervosa and bulimia nervosa, for whom timely interven-
tions are particularly crucial. The identification of reliable
treatment predictors, moderators, and mediators will be es-
pecially useful in determining optimal treatment. Clinical
expertise is essential for tailoring interventions for both
existing and emerging treatments as well as determining
care when empirical data are lacking. Preliminary data sup-
port the potential importance of patient perspectives,
values, and preferences in optimizing treatment outcome,
although the clinical features of eating disorders may com-
plicate this process among individuals who are frightened
of or ambivalent about treatment. Empirical examinations
of emerging treatments may increase the breadth of treat-
ment options supported by data, although the use of clin-
ical expertise and patient preferences and values may help
to develop novel treatments, determine treatment when
evidence-based interventions have not been identified, and
facilitate dissemination and prevention efforts. Finally, fu-
ture investigations are critical, particularly to determine
more efficacious eating disorder treatments, to examine
patient preferences in the context of randomized clinical
trials, and to identify effective treatment dissemination
and implementation strategies to better serve clinicians in
the community providing care to patients.
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